Mike Grey

Executive Chairman

Michael Grey has served as executive chairman since March 2019 and is a co-founder of Mirum.

Mike previously served as chief executive officer from the company’s inception in May 2018 to March 2019. Mr. Grey has served as executive chairman of Amplyx Pharmaceuticals, Inc. since January 2017; Reneo Pharmaceuticals, Inc. since December 2017; and Spruce Biosciences, Inc, since April 2017. He has also served as a venture partner at Pappas Ventures since January 2010 and as president and chief executive officer of Curzion Pharmaceuticals, Inc. Mike served from October 2015 to January 2017 as the president and chief executive officer of Amplyx, and from September 2014 to December 2017 as chairman and chief executive officer of Reneo. From February 2011 to June 2014, Mike served as president and chief executive officer of Lumena, which was acquired by Shire plc in June 2014. Mike has 40 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001) and president of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings PLC, culminating in his position as vice president, corporate development and director of international licensing. Mr. Grey also serves on the boards of directors of BioMarin Pharmaceutical Inc., Horizon Pharma plc and Mirati Therapeutics Inc., each public biotechnology companies.

Mike received a B.Sc. in chemistry from the University of Nottingham in the United Kingdom.

© 2019 – Mirum Pharmaceuticals